View Article

Abstract

Herbal medicine, a cornerstone of traditional healthcare systems, is gaining global attention as a natural and holistic alternative to synthetic pharmaceuticals. Among the numerous medicinal plants, Moringa oleifera and Ocimum sanctum (Tulsi) have emerged as potent therapeutic agents owing to their rich phytochemical profiles and diverse pharmacological properties. Moringa oleifera, often referred to as the "Miracle Tree," is renowned for its high nutritional value and bioactive compounds that exhibit antioxidant, anti-inflammatory, anticancer, and antimicrobial activities. Similarly, Ocimum sanctum, revered in Ayurveda as the "Queen of Herbs," is known for its adaptogenic, immunomodulatory, and antistress effects, supported by constituents such as eugenol, rosmarinic acid, and ursolic acid. This project focuses on the formulation and evaluation of polyherbal tablets combining Moringa oleifera and Ocimum sanctum to harness their synergistic effects for enhanced therapeutic efficacy. Polyherbal formulations offer several advantages, including multi-targeted action, improved bioavailability, reduced toxicity, and a broader spectrum of activity. Herbal tablets provide a convenient and standardized dosage form, promoting compliance and stability while retaining the natural benefits of plant-based medicine. The study underscores the potential of integrating traditional herbal wisdom with modern pharmaceutical approaches to develop safe, effective, and sustainable health solutions.

Keywords

Polyherbal Formulation, Moringa Oleifera, Ocimum Sanctum, Anticancer Activity, Immunomodulatory, Antioxidant

Introduction

Herbal Medicine

Herbal medicine, also known as phytotherapy, is the practice of using medicinal plants and plant-derived substances to prevent or treat various health conditions. It is one of the oldest forms of healthcare in human history and continues to be a vital part of traditional and modern medicine systems, especially in countries like India, China, and many parts of Africa and Latin America. Among the vast range of medicinal plants, Moringa oleifera and Ocimum sanctum—commonly known as Tulsi—stand out for their remarkable therapeutic potential and extensive use in traditional as well as modern healthcare systems. Moringa oleifera, often referred to as the “Miracle Tree,” is native to the Indian subcontinent and is widely cultivated in tropical and subtropical regions. Every part of the Moringa tree, particularly its leaves, is rich in essential nutrients including vitamins A, C, and E, calcium, potassium, and iron. Beyond its nutritional value, Moringa contains a wide range of bioactive compounds such as flavonoids (quercetin, kaempferol), phenolic acids, isothiocyanates, and glucosinolates. These phytochemicals contribute to its diverse pharmacological actions, including antioxidant, anticancer, anti-inflammatory, antidiabetic, antimicrobial, and hepatoprotective effects. Studies have shown that Moringa leaf extracts can neutralize free radicals, inhibit the growth of cancer cells, reduce inflammatory mediators, and support immune modulation, making it a potent natural agent for chronic disease management. Ocimum sanctum, commonly known as Tulsi or Holy Basil, holds sacred significance in Indian culture and is revered as the "Queen of Herbs" in Ayurveda. It is a well-known adaptogen and is valued for promoting longevity, resilience, and vitality. Tulsi is rich in pharmacologically active constituents such as eugenol, ursolic acid, rosmarinic acid, apigenin, and carvacrol, which endow it with powerful anti-inflammatory, immunomodulatory, antioxidant, antimicrobial, and antistress properties. Scientific studies have validated Tulsi’s efficacy in enhancing immune function, reducing oxidative stress, improving respiratory health, and protecting against chemical-induced toxicity. It has also demonstrated antimicrobial activity against a range of bacterial, viral, and fungal pathogens, making it useful in supporting the body’s defense mechanisms. Together, Moringa and Tulsi represent a synergy of nutrition and pharmacology, offering a comprehensive profile of therapeutic benefits that address oxidative stress, inflammation, immune dysregulation, and cellular damage—factors that are central to many chronic and lifestyle-related diseases. Their use in traditional systems is now being increasingly supported by modern scientific methodologies, including phytochemical analysis, in vitro and in vivo pharmacological studies, and clinical trials. With the integration of traditional knowledge and contemporary research, these herbs are paving the way for the development of effective, safe, and natural health-supporting formulations that align with global health priorities and sustainable wellness. Herbal medicines are generally considered to be safe, cost-effective, and environmentally friendly. However, their effectiveness depends on proper selection, standardization, formulation, and quality control of the plant materials used.

Key Advantages of Polyherbal Formulations:

  • Synergistic Action

The therapeutic effect of combined herbs may be greater than the sum of their individual effects. One herb may enhance the efficacy or absorption of another, leading to improved overall outcomes.

  • Multi-targeted Approach

Polyherbal formulations can act on multiple biological pathways simultaneously, making them particularly useful in the management of complex and chronic diseases such as cancer, diabetes, and inflammatory disorders.

  • Enhanced Bioavailability

Certain herbs in the formulation may increase the solubility, absorption, or stability of active compounds from other herbs, thereby improving the overall bioavailability of the preparation.

  • Reduced Toxicity and Side Effects

Combining herbs allows for the use of lower doses of individual components, which can reduce the likelihood of adverse effects while maintaining or enhancing therapeutic efficacy.

  • Broader Therapeutic Spectrum

Polyherbal formulations typically include herbs with different pharmacological activities—such as antioxidant, immunomodulatory, antimicrobial, and adaptogenic properties—offering comprehensive treatment.

  • Improved Stability and Preservation

Some plant constituents possess natural antioxidant or antimicrobial properties that help stabilize the overall formulation and prolong shelf life.

  • Prevention of Resistance

In infectious or cancer therapies, the use of multiple bioactive compounds with varied mechanisms of action helps prevent the development of resistance in pathogens or tumor cells.

Herbal Tablet Overview:

  • Definition and Composition:
    Herbal tablets are solid dosage forms that are designed to deliver medicinal benefits from plants in a compact and easy-to-administer form. These tablets are typically made by compressing powdered herbs or herbal extracts (such as aqueous or ethanolic extracts) into solid shapes.
  • Types of Herbal Tablets:
    • Conventional tablets: Designed for rapid release of active ingredients.
    • Controlled-release tablets: Formulated to release active ingredients gradually over time, providing prolonged effects.
    • Chewable tablets: Easy to chew and often formulated for children or those who have difficulty swallowing pills.

Importance of Herbal Tablets:

  • Natural Alternative to Pharmaceuticals:
    Herbal tablets offer a natural alternative to synthetic drugs. They provide an option for individuals seeking relief from various health issues with minimal risk of side effects, especially in conditions where natural healing is preferred or required.
  • Therapeutic Benefits:
    • Anti-inflammatory: Herbs like turmeric and ginger are widely used in tablet formulations for their anti-inflammatory properties.
    • Antioxidant: Plants like Moringa Oleifera contain powerful antioxidants that combat oxidative stress.
    • Immune Boosting: Tulsi (Ocimum sanctum) and Echinacea are used for enhancing the immune system.
  • Growing Market Demand:
    With increasing awareness and a preference for holistic health, there is a growing demand for natural remedies. Many consumers now prefer herbal treatments over conventional drugs due to concerns about the side effects of synthetic drugs.

Growing Popularity of Herbal Tablets:

  • Consumer Preferences for Natural Products:

Increasing health awareness has led to a surge in the demand for herbal tablets. Consumers are seeking natural, plant-based treatments for everyday health issues like digestive problems, stress management, immune support, and skin health.

  • Wide Use for Chronic Conditions:

Many herbal tablets are used to manage chronic health conditions such as arthritis, high blood pressure, diabetes, and respiratory disorders. Herbs like turmeric, garlic, and ginger are popular for their anti-inflammatory properties and antioxidant activity.

Market Expansion:

With the global interest in wellness and natural products, the market for herbal tablets continues to grow, with many companies focusing on developing herbal products that meet the needs of the wellness-conscious consumer. Organic certification and sustainable sourcing are becoming key considerations for consumers when selecting herbal products.

Drug Profile:

  1. Moringa oleifera:

Moringa oleifera, also known as the drumstick tree or Moringa, is native to regions of South Asia and Africa. The plant is renowned for its nutritional value and medicinal properties, particularly for its anticancer, anti-inflammatory, and antioxidant effects.

Key Bioactive Compounds in Moringa

  • Isothiocyanates
  • Flavonoids
  • Phenolic Acids

Moringa's Anticancer Mechanisms

Tulsi (Ocimum sanctum):

Tulsi (Ocimum sanctum), or Holy Basil, is considered a sacred plant in Hindu culture and is widely used in traditional medicine for its medicinal properties. The plant is rich in essential oils, flavonoids, and alkaloids, which have demonstrated a wide range of anticancer effects.

Key Bioactive Compounds in Tulsi

  • Eugenol
  • Rosmarinic Acid
  • Ursolic Acid

Tulsi's Anticancer Mechanisms:

Synergistic Effects of Moringa and Tulsi in Cancer Therapy

When combined, the anticancer properties of Moringa oleifera and Tulsi (Ocimum sanctum) are enhanced, offering a multifaceted approach to cancer treatment. These plants provide complementary bioactive compounds that can work in concert to:

• Enhance Apoptotic Pathways: Both Moringa and Tulsi contain compounds that activate apoptosis through distinct pathways, increasing the overall effectiveness in killing cancer cells.

• Suppress Tumor Growth and Metastasis: By inhibiting angiogenesis, metastasis, and tumor progression, the combination of Moringa and Tulsi helps prevent the spread of cancer.

• Regulate Oxidative Stress and Inflammation: The combination of antioxidants and anti-inflammatory agents from both plants reduces the molecular pathways that fuel cancer development and progression.

• Complement Conventional Cancer Treatments: Moringa and Tulsi may act as adjuvants to conventional therapies, reducing the side effects of chemotherapy and radiation while boosting the immune system and promoting recovery.

Literature Review

1. Al-Asmari et al. (2015)

Investigated Moringa oleifera extracts against breast and colorectal cancer cell lines. Results revealed dose-dependent cytotoxicity with inhibition of proliferation and induction of apoptosis in MCF-7 and HCT-8 cells.
PLOS ONE, 10(8): e0135814.

2. Saini et al. (2016)

Reviewed the phytochemical profile of Moringa oleifera, identifying quercetin, kaempferol, and niazimicin as key anticancer compounds. These phytochemicals have antioxidant, anti-inflammatory, and antiproliferative properties.
3 Biotech, 6:203.

3. Manikandan et al. (2007)

Explored ethanolic extracts of Ocimum sanctum and reported significant apoptosis in oral squamous carcinoma cells via caspase activation and ROS modulation.
Cell Biochemistry and Function, 25(2): 189–194.

4. Mondal et al. (2009)

A comprehensive review of Tulsi’s pharmacological profile highlights anticancer effects, particularly via modulation of antioxidant defense and immune response.
International Journal of Clinical Pharmacology and Therapeutics, 47(11): 601–612.

5. Bharali et al. (2003)

Demonstrated that Moringa oleifera leaf extract can significantly reduce tumor burden in mice models bearing Dalton’s lymphoma, attributed to its antiangiogenic and cytotoxic properties.
Indian Journal of Experimental Biology, 41(11): 1239–1243.

6. Siddiqui et al. (2013)

Found that Ocimum sanctum modulates key carcinogenic pathways such as NF-κB, STAT3, and COX-2, suggesting chemopreventive potential.
Nutritional and Cancer, 65(Suppl 1): 26–34.

7. Tiloke et al. (2013)

Explored the molecular effects of Moringa oleifera in A549 lung cancer cells. The extract triggered DNA fragmentation, reduced mitochondrial membrane potential, and caused apoptosis.
Asian Pacific Journal of Cancer Prevention, 14(10): 6067–6072.

8. Goyal et al. (2011)

Outlined Moringa oleifera’s role as a chemopreventive agent, including its suppression of oxidative stress, DNA damage, and pro-inflammatory markers.
Phytotherapy Research, 25(1): 17–25.

9. Prakash & Gupta (2005)

Summarized Tulsi's traditional and modern applications, including its anticancer effects through adaptogenic and detoxification pathways.
Journal of Ethnopharmacology, 93(1): 1–15.

10. Verma et al. (2013)

Reported that Moringa’s benzyl isothiocyanate exhibits strong antiproliferative effects in prostate and pancreatic cancer cell lines via apoptotic signaling.
Cancer Letters, 341(1): 30–38.

11. Pattanayak et al. (2010)

Validated Tulsi’s role in cancer management, citing its ability to scavenge free radicals and suppress tumor promotion through epigenetic modulation. Pharmacognosy Reviews, 4(7): 95–105.

Aim

To formulate, standardize, and evaluate a polyherbal tablet comprising Moringa oleifera and Ocimum sanctum, exploring its physicochemical, phytochemical, and potential anticancer properties for integrative therapeutic use.

Objectives

  1. To authenticate the selected medicinal plants
    Confirm the identity and purity of Moringa oleifera and Ocimum sanctum using macroscopic, microscopic, and powder microscopy techniques in accordance with Ayurvedic and pharmacopoeial standards.
  2. To prepare and standardize the herbal powders
    Subject both plant materials to proper drying, pulverization, and sieving, ensuring a consistent particle size and stability suitable for tablet formulation.
  3. To develop a polyherbal tablet formulation
    Combine Moringa and Tulsi powders in a 5:1 ratio (250 mg:50 mg) with optimized pharmaceutical excipients for tablet cohesion, disintegration, and flow properties.
  4. To evaluate physicochemical characteristics of the tablet
    Analyze critical quality parameters such as tablet hardness, friability, weight variation, disintegration time, moisture content, and in vitro dissolution behavior.
  5. To quantify bioactive compounds using analytical methods
    Employ UV-Visible spectroscopy or High-Performance Liquid Chromatography (HPLC) for standardization by estimating marker compounds like quercetin, eugenol, and ursolic acid.
  6. To ensure stability and quality consistency
    Conduct short-term stability testing under accelerated conditions to examine any physical, chemical, or pharmacological changes in the formulation.

Plan Of Work

1. Literature Review & Plant Authentication

O Conduct a thorough review of existing literature on the pharmacological properties of Moringa oleifera and Ocimum sanctum, focusing on their anticancer, antioxidant, anti-inflammatory, and immunomodulatory effects.

O Authenticate the plant materials using botanical and pharmacognostic methods to ensure proper identification and quality.

2. Collection and Preparation of Plant Materials

O Source fresh leaves of Moringa and Tulsi from certified suppliers or cultivation areas.

O Dry the leaves at controlled temperatures to preserve bioactive compounds, then grind them into fine powders suitable for tablet formulation.

3. Formulation Development

O Develop the polyherbal tablet formulation with Moringa (250 mg) and Tulsi (50 mg) per tablet, ensuring the total active ingredient (API) content comprises 60% of the tablet weight.

O Select appropriate excipients (binders, fillers, lubricants, disintegrants) to ensure tablet cohesion, stability, and ease of manufacture.

O Conduct preliminary formulation trials to optimize the composition for efficacy and stability.

4. Tablet Evaluation (Physicochemical Testing)

O Conduct essential quality control tests, such as hardness, friability, disintegration time, and dissolution rate, to ensure the formulation meets pharmaceutical standards for tablet quality and performance.

5. Quantification of Bioactive Compounds

O Use HPLC or UV-Vis spectroscopy to quantify active compounds (e.g., quercetin, eugenol, ursolic acid) in the final tablet formulation.

O Standardize the formulation based on the active compound content, ensuring the desired therapeutic potency.

6. Stability and Shelf-life Testing

O Test the stability of the tablets under different environmental conditions, such as varying temperature and humidity.

O Monitor physical and chemical changes over time, including degradation of active compounds, and assess the shelf life of the formulation.

Material And Equipment

1. Raw Plant Materials

Raw Plant Material

Purpose

Moringa oleifera leaf powder

Active ingredient for anticancer, antioxidant, and other therapeutic effects

Tulsi (Ocimum sanctum) leaf powder

Active ingredient for anti-inflammatory, immunomodulatory effects

2.Excipients

Excipient

Example

Purpose

Binder

Microcrystalline cellulose (MCC)

Helps in granule formation, improves tablet cohesion, and ensures consistency in tablet size and structure

Filler

Lactose / Calcium phosphate

Increases tablet bulk, improves compressibility, and provides a base for the active ingredients

Disintegrant

Croscarmellose sodium

Ensures rapid breakdown of tablets in the digestive system, facilitating faster absorption of the active ingredients

Glidant

Colloidal silicon dioxide

Improves powder flow during tablet formation, preventing clumping and ensuring smooth compression

Lubricant

Magnesium stearate

Prevents sticking during compression, ensuring smooth tablet ejection and reducing friction in the machine

Granulating Agent

Purified water or alcohol

Used for wet granulation to bind active ingredients and excipients, ensuring uniformity and consistency of the tablet mixture

3.Testing Equipment

Testing Equipment

Purpose

Tablet Dissolution Apparatus

To measure the rate and extent of dissolution of the tablet in a specified medium (usually simulated gastric fluid).

Tablet Disintegration Tester

To determine the time required for a tablet to disintegrate into smaller particles under controlled conditions.

Tablet Hardness Tester

To measure the hardness or crushing strength of the tablet, ensuring its mechanical integrity during handling and storage.

Tablet Friability Tester

To assess the tablet's resistance to breaking or crumbling under stress, simulating handling during transport.

Tablet Weight Variation Tester

To check the uniformity of tablet weight, ensuring consistency across tablets in a batch.

Tablet Thickness and Diameter Tester

To measure the uniformity of tablet dimensions to ensure consistent size and appearance.

UV-Vis Spectrophotometer

To analyze the concentration of active ingredients or degradation products in the formulation.

pH Meter

To measure the pH of the tablet dissolution medium and ensure it falls within the required range for the intended therapeutic use.

Experimental Work

  1. Pre-Manufacturing Preparations

Step 1: Cleaning and Sanitization

Equipment Used:

    • Cleaning agents (70% ethanol, disinfectants)
    • Stainless steel weighing balance
    • Blender, Granulator, Sieves, Tray dryer, Tablet press
    • Hardness Tester, Friability Tester, Disintegration Tester
    • Stainless steel trays, spatulas, gloves, and masks

Procedure:

1. Equipment Cleaning:

o Disassemble all processing equipment (if applicable).

o Clean each part using an appropriate cleaning solution.

o Use hot water and mild detergent for primary cleaning, followed by 70% ethanol for disinfection.

  1. Sanitization of Work Area:
      • Wipe down work surfaces, tables, and floors with disinfectant.
      • Ensure the tablet compression area is free from dust and contaminants.
      • Mop the production area with approved disinfectant solution.
  2. Operator Hygiene:

o Operators must wear sterile gloves, masks, lab coats, and hairnets before entering the manufacturing area.

 o Ensure hands are sanitized before handling materials.

Step 2: Raw Material Weighing

Equipment Used:

  • Digital Weighing Balance (Calibrated)
  • Stainless Steel Trays
  • Glass Beakers & Measuring Cylinders

Procedure:

  1. Tare the balance before weighing to ensure accuracy.
  2. Weigh each ingredient as per formulation:
  3. Cross-check each measurement against the formulation sheet.
  4. Transfer weighed materials into labeled stainless steel trays for easy identification.
  1. Manufacturing Process

Step 3: Dry Blending

Equipment Used:

    • High-Speed Mixer / Blender
    • Mortar & Pestle (for small batches)
    • Stainless steel scoops and spatulas

Procedure:

    1. Transfer the API (Moringa Oleifera leaf powder), binder, filler, and disintegrant into the blender.
    2. Mix at low speed (30–40 rpm) for 10–15 minutes to ensure uniform distribution.
    3. If using a mortar and pestle, blend in circular motions until homogenous.
    4. Visually inspect the uniformity of the blend.

Step 4: Wet Granulation

Equipment Used:

    • Granulator
    • Measuring Cylinder, Stirring Rod

Procedure:

    1. Prepare the binder solution using purified water or alcohol.
    2. Slowly add the binding solution to the dry mix while continuously stirring.
    3. Mix until wet granules form with a slightly damp, non-sticky texture.

Instructions:

    • Ensure the granules are not overly wet, as excessive moisture can lead to poor drying.
    • Stop mixing when the granules form a soft clump that easily breaks upon pressure.  

Step 5: Wet Sieving (Granule Sizing Before Drying)

Purpose:

    • To break down large lumps formed during wet granulation.
    • To ensure uniform granule size, improving drying efficiency.
    • To eliminate ungranulated fine powder, ensuring batch consistency.

Equipment Used:

    • 16-Mesh Stainless Steel Sieve (For wet granule sizing)
    • Wet Granulator / Hand Sieving Setup
    • Stainless Steel Trays
    • Spatula / Wooden Spoon

Procedure:

Prepare Sieving Equipment:

• Place a 16-mesh sieve over a stainless-steel collection tray.

• Ensure the sieve is clean and dry before use.

• Transfer Wet Granules:

• Carefully transfer freshly prepared wet granules onto the sieve.

• Do not overload the sieve, as excessive material may reduce efficiency.

• Sieving Process:

• Using a spatula or wooden spoon, gently press the granules through the mesh.

• Move the material circularly to break down lumps.

• Continue sieving until most granules pass through, leaving only large ungranulated lumps.

Reprocessing Oversized Granules:

• If there are large unprocessed lumps, return them to the granulation stage.

• Adjust binder or liquid content if excessive large lumps form.

• Collect and Transfer:

• Transfer sieved wet granules into stainless steel trays for drying.

• Label each batch correctly for tracking. 

Step 6: Drying of Granules

Equipment Used:

• Tray Dryer / Hot Air Oven

• Stainless Steel Drying Trays

Procedure:

    1. Spread granules evenly on trays and dry at 40–50°C for 30–60 minutes.
    2. Ensure moisture content is below 5% before proceeding.

Instructions:

    • Use a Moisture Analyzer to check the residual moisture content.

Step 7: Dry Sieving (Granule Sizing After Drying) Purpose:

    • To achieve uniform particle size after drying.
    • To eliminate fine dust or oversized granules.
    • To improve flow properties, preventing tablet weight variation.

Equipment Used:

    1. 20-Mesh Stainless Steel Sieve (For dry granule sizing)
    2. Vibratory Sifter or Manual Sieving Setup
    3. Stainless Steel Collection Trays
    4. Spatula / Brush for Cleaning Sieve

Procedure:

1. Prepare Sieving Setup:

      • Place a 20-mesh sieve over a collection tray.
      • Ensure sieve is completely dry before starting the process.

2. Load Dried Granules:

      • Transfer fully dried granules onto the sieve.
      • Spread evenly to avoid clogging.
  1. Sieving Process:
      • Gently shake or tap the sieve to allow granules to pass through.
      •  If using a vibratory sifter, set the vibration speed to low-medium to prevent breaking granules.
      • If manually sieving, rotate the material gently using a spatula.
  2. Collection of Final Granules:

o Collect uniform-sized granules in the stainless steel tray.

 o If fine powder is excessive (>10% of batch weight), consider regranulation to minimize losses.

  1. Handling Oversized Particles:
      • Any granules that do not pass through the 20-mesh sieve should be reprocessed (reduced in size using a mortar & pestle or granulator) and re-sieved.
      • If too many fines are present, adjust granulation parameters in future batches records of sieve efficiency and batch uniformity.   

Step 8: Lubrication and Final Blending

Equipment Used:

  • Blender / Mixer

Procedure:

  1. Add Glidant (Colloidal Silicon Dioxide) and Lubricant (Magnesium Stearate) to granules.
  2. Mix for 5 minutes to ensure even distribution.

Step 9: Tablet Punching (Compression) Process

Equipment Used:

  1. Rotary Tablet Press Machine / Single-Punch Tablet Press
  2. Tablet Compression Tooling (Punches & Dies – 10 mm standard round shape)
  3. Hopper for granule feeding
  4. Compression Force Adjustment Knob
  5. Dust Extraction System
  6. Tablet De-duster (Optional, for removing excess powder from tablets

Compression Process

  • Set the tablet weight and thickness using the machine control panel.
  • Adjust the compression force (typically 4–6 kg/cm² for herbal tablets).
  • Start the tablet press at a slow speed for trial punches.
  • Observe the tablet ejection, ensuring no sticking or capping occurs.

Instruction: Compression force should be optimized to prevent tablet friability (breaking) or lamination (layer separation).

Formulation Images

RESULT

Organoleptic Evaluation of Formulated Tablets

Parameter

Batch A

Batch B

Batch C

Color

Greenish

Greenish

Greenish

Odor

Herbal, characteristic

Herbal, characteristic

Herbal, characteristic

Taste

Slightly bitter

Slightly bitter

Slightly bitter

Texture

Smooth, uniform

Smooth, uniform

Smooth, uniform

2. Physical Evaluation of Tablets

Parameter

Batch A

Batch B

Batch C

Limits

Avg. Weight (mg)

500.3 ± 1.9

499.8 ± 2.1

501.2 ± 2.3

±5% of label claim

Thickness (mm)

4.3 ± 0.1

4.2 ± 0.1

4.3 ± 0.1

Consistent

Hardness (kg/cm²)

5.8 ± 0.3

5.7 ± 0.4

5.6 ± 0.3

4–8

Friability (%)

0.36

0.34

0.38

NMT 1%

Disintegration (min)

4.6

4.4

4.5

NMT 15 min

pH

6.3

6.4

6.4

5.5 – 7.5 (acceptable)

Dissolution

84.5%

82.7%

85.3%

NMT 80%

3. Phytochemical Screening (All Batches)

Phytochemical

Batch A

Batch B

Batch C

Remarks

Alkaloids

Present

Present

Present

Potential anticancer & antimicrobial

Flavonoids

Present

Present

Present

Strong antioxidant activity

Tannins

Present

Present

Present

Astringent & anti-inflammatory

Saponins

Present

Present

Present

Immune-boosting & surfactant property

Terpenoids

Present

Present

Present

Cytotoxic, anti-inflammatory

Phenols

Present

Present

Present

Radical scavenging

4. UV-Visible Spectroscopic Analysis

Parameter

Batch A

Batch B

Batch C

Reference Values

λmax (Eugenol)

282 nm

283 nm

282 nm

280–285 nm (Tulsi)

λmax (Quercetin)

370 nm

371 nm

370 nm

365–375 nm (Moringa)

Flavonoid Content (mg/g)

18.2

18.6

18.4

15–25

Phenolic Content (mg/g)

24.5

24.9

24.7

20–30

SUMMARY AND CONCLUSION

Summary

The study focused on the development of a 500 mg polyherbal tablet formulation containing Moringa oleifera and Tulsi (Ocimum sanctum) as primary active ingredients. Moringa (250 mg per tablet) and Tulsi (50 mg per tablet) were selected for their known anticancer, antioxidant, anti-inflammatory, and immunomodulatory properties, forming a 60% active ingredient composition in the tablet.

Key Ingredients and Excipients:

  • Moringa oleifera: Known for its potent antioxidant and anticancer activities, rich in bioactive compounds such as flavonoids and phenolic acids.
  • Tulsi (Ocimum sanctum): Contains eugenol and ursolic acid, contributing anti-inflammatory and adaptogenic effects.

The excipients used in the formulation included:

  • Microcrystalline cellulose (50 mg), acting as a binder.
  • Lactose (or Calcium phosphate) (50 mg), serving as a filler.
  • Croscarmellose sodium (20 mg), used as a disintegrant to enhance the tablet’s breakdown during digestion.
  • Colloidal silicon dioxide (10 mg) for powder flow and magnesium stearate (10 mg) to act as a lubricant.

Manufacturing Process:

The tablets were produced through the wet granulation method, followed by compression to ensure optimal tablet consistency and stability.

Evaluation and Analysis:

Three batches (A, B, and C) of the tablet formulation were prepared and subjected to various physical and chemical tests:

  1. Physical Evaluation:
    Tablets were assessed for weight uniformity, hardness, friability, and disintegration time, all of which met the specified pharmaceutical standards.
  2. Organoleptic Characteristics:
    The tablets exhibited characteristic greenish-brown color, a herbal odor, and a slightly bitter taste, which is typical for plant-based formulations.
  3. UV-Visible Spectroscopy:
    The UV absorbance peaks for eugenol (Tulsi) and quercetin (Moringa) confirmed the presence of key bioactive components and validated the formulation's chemical consistency.

CONCLUSION

1. The 500 mg polyherbal tablet formulation using Moringa oleifera and Tulsi was successfully developed, showing consistency and stability across three batches.

2. The formulation met the required physical parameters, ensuring quality and uniformity in weight, hardness, friability, and disintegration.

3. Phytochemical screening confirmed the presence of active compounds such as alkaloids, flavonoids, tannins, and saponins, which are known for their therapeutic benefits.

4. The UV-Vis spectroscopy analysis confirmed the presence of marker compounds like eugenol (Tulsi) and quercetin (Moringa), ensuring the chemical consistency of the formulation.

5. The formulation shows multi-therapeutic potential, focusing not only on anticancer activity but also offering benefits like antioxidant, anti-inflammatory, and immunomodulatory effects.

6. The polyherbal tablet formulation is a safe, effective, and promising natural therapeutic option and can potentially be further developed for clinical trials to establish its efficacy and broader applications.

REFERENCES

  1. Gurib-Fakim, Ameenah. “Medicinal Plants: Traditions of Yesterday and Drugs of Tomorrow.” Molecular Aspects of Medicine, vol. 27, no. 1, 2006, pp. 1–93.
  2. Fabricant, Daniel S., and Norman R. Farnsworth. “The Value of Plants Used in Traditional Medicine for Drug Discovery.” Environmental Health Perspectives, vol. 109, suppl. 1, 2001, pp. 69–75.
  3. Ekor, Martins. “The Growing Use of Herbal Medicines: Issues Relating to Adverse Reactions and Challenges in Monitoring Safety.” Frontiers in Pharmacology, vol. 4, 2014, p. 177.
  4. World Health Organization. WHO Traditional Medicine Strategy 2014–2023. World Health Organization, 2013.
  5. Patwardhan, Bhushan, et al. “Ayurveda and Traditional Chinese Medicine: A Comparative Overview.” Evidence-Based Complementary and Alternative Medicine, vol. 2, no. 4, 2005, pp. 465–473.
  6. Wagner, Hildebert, and Gudrun Ulrich-Merzenich. “Synergy Research: Approaching a New Generation of Phytopharmaceuticals.” Phytomedicine, vol. 16, no. 2–3, 2009, pp. 97–110.
  7. Kunle, Folashade O., Hope O. Egharevba, and Peter O. Ahmadu. “Standardization of Herbal Medicines – A Review.” International Journal of Biodiversity and Conservation, vol. 4, no. 3, 2012, pp. 101–112.
  8. European Medicines Agency. Guideline on Quality of Herbal Medicinal Products/Traditional Herbal Medicinal Products. EMA/HMPC, 2006.
  9. Williamson, Elizabeth M. “Synergy and Other Interactions in Phytomedicines.” Phytomedicine, vol. 8, no. 5, 2001, pp. 401–409.
  10. Zhang, Aihua, et al. “Modern Analytical Techniques in Traditional Chinese Medicine: Progress, Challenges and Future Perspectives.” The Analyst, vol. 137, no. 3, 2012, pp. 297–304.
  11. Williamson, Elizabeth M. “Synergy and Other Interactions in Phytomedicines.” Phytomedicine, vol. 8, no. 5, 2001, pp. 401–409.
  12. Zhang, Aihua, et al. “Modern Analytical Techniques in Traditional Chinese Medicine: Progress, Challenges and Future Perspectives.” The Analyst, vol. 137, no. 3, 2012, pp. 297–304.
  13. Heinrich, Michael, et al. Fundamentals of Pharmacognosy and Phytotherapy. Elsevier Health Sciences, 2012.
  14. Cowan, Marjorie M. “Plant Products as Antimicrobial Agents.” Clinical Microbiology Reviews, vol. 12, no. 4, 1999, pp. 564–582.
  15. Saini, Rajesh K., Inbathamizh L. Sivanesan, and Yong-Soo Keum. “Phytochemicals of Moringa oleifera and Their Therapeutic Importance: A Review.” 3 Biotech, vol. 6, no. 2, 2016, p. 203.
  16. Al-Asmari, Abdulrahman K., et al. “Moringa oleifera as an Anti-Cancer Agent against Breast and Colorectal Cancer Cell Lines.” PLOS ONE, vol. 10, no. 8, 2015, e0135814.
  17. Mondal, Subhasree, et al. “Scientific Validation of Holy Basil (Ocimum sanctum Linn.) as an Herbal Remedy and Its Therapeutic Applications: A Review.” International Journal of Clinical Pharmacology and Therapeutics, vol. 47, no. 11, 2009, pp. 601–612.
  18. Manikandan, P., et al. “Ocimum sanctum Extracts Induce Apoptosis in Oral Cancer Cells.” Cell Biochemistry and Function, vol. 25, no. 2, 2007, pp. 189–194.
  19. Bhatnagar, P., & Ghosal, S. (2003). "Moringa oleifera: A Review on Its Medicinal Properties." Indian Journal of Natural Products and Resources, 3(4), 340-344.
  20. Mishra, R. (2012). "Tulsi (Ocimum sanctum): A Herb for the Treatment of Various Diseases." International Journal of Pharma and Bio Sciences, 3(1), 47-52.
  21. Kumar, P., & Tiwari, S. (2015). "Phytochemistry, Pharmacology, and Therapeutic Applications of Tulsi (Ocimum sanctum): A Review." International Journal of Pharmacognosy and Phytochemical Research, 7(3), 301-305.
  22. Gopalakrishnan, S., & Murugesan, S. (2017). "Moringa Oleifera: A Review on Its Nutritional and Medicinal Benefits." Pharmacognosy Reviews, 11(22), 74-81.
  23. Bender, M. (2015). "Pharmaceutical Excipients: An Overview." American Pharmaceutical Review, 18(1), 58-65.
  24. Lachman, L., Lieberman, H. A., & Kanig, J. L. (2017). The Theory and Practice of Industrial Pharmacy. 4th ed. Lea & Febiger, Philadelphia.
  25. Aulton, M. E., & Taylor, K. (2013). Aulton's Pharmaceutics: The Design and Manufacture of Medicines. 4th ed. Churchill Livingstone, Edinburgh.
  26. Khan, M. A., & Marshall, K. (2003). "Excipients in Pharmaceutical Formulations." Pharmaceutical Technology, 27(5), 72-79.
  27. Thakur, A. R., & Rathi, S. (2013). "Pharmaceutical Tablet Testing: Dissolution, Disintegration, Hardness, and Friability." Journal of Pharmaceutical Sciences and Research, 5(2), 116-122.
  28. Tosun, A. (2012). "Quality Control Testing of Pharmaceutical Tablets." Journal of Applied Pharmaceutical Science, 2(7), 34-39.
  29. Garg, S., & Gupta, G. D. (2014). "Dissolution Testing of Pharmaceutical Dosage Forms." Indian Journal of Pharmaceutical Sciences, 76(1), 1-8.
  30. Bajaj, A., & Khurana, V. (2017). "Testing of Pharmaceutical Tablets: Techniques and Instruments." Asian Journal of Pharmaceutical Technology and Innovation, 5(9), 1-6.
  31. Lachman, L., Lieberman, H. A., & Kanig, J. L. (1991). "The Theory and Practice of Industrial Pharmacy" (3rd Edition). Bombay: Varghese Publishing House.
  32. Shargel, L., Wu-Pong, S., Yu, A. B. C. (2012). "Applied Biopharmaceutics & Pharmacokinetics" (6th Edition). McGraw-Hill Education.
  33. ICH Q8(R2) – Pharmaceutical Development Guidelines Focuses on granulation, drying, and compression for solid dosage forms.
  34. USP General Chapter <1174> Powder Flow o Guidelines for granule flowability before tablet compression.
  35. Pharmaceutical Powder Technology – Martin’s Physical Pharmacy & Pharmaceutical Sciences (7th Edition).
  36. British Pharmacopoeia (BP) – Sieving Techniques & Particle Size Distribution o British Pharmacopoeia .
  37. USP General Chapter <786> "Particle Size Distribution Estimation by Analytical Sieving.
  38. United States Pharmacopeia (USP) – General Chapter <1062> "Tablet Compression" Provides guidance on tablet hardness, thickness, and weight variation.
  39. European Pharmacopoeia (EP) – Tablet Compression Standards European Pharmacopoeia.

Reference

  1. Gurib-Fakim, Ameenah. “Medicinal Plants: Traditions of Yesterday and Drugs of Tomorrow.” Molecular Aspects of Medicine, vol. 27, no. 1, 2006, pp. 1–93.
  2. Fabricant, Daniel S., and Norman R. Farnsworth. “The Value of Plants Used in Traditional Medicine for Drug Discovery.” Environmental Health Perspectives, vol. 109, suppl. 1, 2001, pp. 69–75.
  3. Ekor, Martins. “The Growing Use of Herbal Medicines: Issues Relating to Adverse Reactions and Challenges in Monitoring Safety.” Frontiers in Pharmacology, vol. 4, 2014, p. 177.
  4. World Health Organization. WHO Traditional Medicine Strategy 2014–2023. World Health Organization, 2013.
  5. Patwardhan, Bhushan, et al. “Ayurveda and Traditional Chinese Medicine: A Comparative Overview.” Evidence-Based Complementary and Alternative Medicine, vol. 2, no. 4, 2005, pp. 465–473.
  6. Wagner, Hildebert, and Gudrun Ulrich-Merzenich. “Synergy Research: Approaching a New Generation of Phytopharmaceuticals.” Phytomedicine, vol. 16, no. 2–3, 2009, pp. 97–110.
  7. Kunle, Folashade O., Hope O. Egharevba, and Peter O. Ahmadu. “Standardization of Herbal Medicines – A Review.” International Journal of Biodiversity and Conservation, vol. 4, no. 3, 2012, pp. 101–112.
  8. European Medicines Agency. Guideline on Quality of Herbal Medicinal Products/Traditional Herbal Medicinal Products. EMA/HMPC, 2006.
  9. Williamson, Elizabeth M. “Synergy and Other Interactions in Phytomedicines.” Phytomedicine, vol. 8, no. 5, 2001, pp. 401–409.
  10. Zhang, Aihua, et al. “Modern Analytical Techniques in Traditional Chinese Medicine: Progress, Challenges and Future Perspectives.” The Analyst, vol. 137, no. 3, 2012, pp. 297–304.
  11. Williamson, Elizabeth M. “Synergy and Other Interactions in Phytomedicines.” Phytomedicine, vol. 8, no. 5, 2001, pp. 401–409.
  12. Zhang, Aihua, et al. “Modern Analytical Techniques in Traditional Chinese Medicine: Progress, Challenges and Future Perspectives.” The Analyst, vol. 137, no. 3, 2012, pp. 297–304.
  13. Heinrich, Michael, et al. Fundamentals of Pharmacognosy and Phytotherapy. Elsevier Health Sciences, 2012.
  14. Cowan, Marjorie M. “Plant Products as Antimicrobial Agents.” Clinical Microbiology Reviews, vol. 12, no. 4, 1999, pp. 564–582.
  15. Saini, Rajesh K., Inbathamizh L. Sivanesan, and Yong-Soo Keum. “Phytochemicals of Moringa oleifera and Their Therapeutic Importance: A Review.” 3 Biotech, vol. 6, no. 2, 2016, p. 203.
  16. Al-Asmari, Abdulrahman K., et al. “Moringa oleifera as an Anti-Cancer Agent against Breast and Colorectal Cancer Cell Lines.” PLOS ONE, vol. 10, no. 8, 2015, e0135814.
  17. Mondal, Subhasree, et al. “Scientific Validation of Holy Basil (Ocimum sanctum Linn.) as an Herbal Remedy and Its Therapeutic Applications: A Review.” International Journal of Clinical Pharmacology and Therapeutics, vol. 47, no. 11, 2009, pp. 601–612.
  18. Manikandan, P., et al. “Ocimum sanctum Extracts Induce Apoptosis in Oral Cancer Cells.” Cell Biochemistry and Function, vol. 25, no. 2, 2007, pp. 189–194.
  19. Bhatnagar, P., & Ghosal, S. (2003). "Moringa oleifera: A Review on Its Medicinal Properties." Indian Journal of Natural Products and Resources, 3(4), 340-344.
  20. Mishra, R. (2012). "Tulsi (Ocimum sanctum): A Herb for the Treatment of Various Diseases." International Journal of Pharma and Bio Sciences, 3(1), 47-52.
  21. Kumar, P., & Tiwari, S. (2015). "Phytochemistry, Pharmacology, and Therapeutic Applications of Tulsi (Ocimum sanctum): A Review." International Journal of Pharmacognosy and Phytochemical Research, 7(3), 301-305.
  22. Gopalakrishnan, S., & Murugesan, S. (2017). "Moringa Oleifera: A Review on Its Nutritional and Medicinal Benefits." Pharmacognosy Reviews, 11(22), 74-81.
  23. Bender, M. (2015). "Pharmaceutical Excipients: An Overview." American Pharmaceutical Review, 18(1), 58-65.
  24. Lachman, L., Lieberman, H. A., & Kanig, J. L. (2017). The Theory and Practice of Industrial Pharmacy. 4th ed. Lea & Febiger, Philadelphia.
  25. Aulton, M. E., & Taylor, K. (2013). Aulton's Pharmaceutics: The Design and Manufacture of Medicines. 4th ed. Churchill Livingstone, Edinburgh.
  26. Khan, M. A., & Marshall, K. (2003). "Excipients in Pharmaceutical Formulations." Pharmaceutical Technology, 27(5), 72-79.
  27. Thakur, A. R., & Rathi, S. (2013). "Pharmaceutical Tablet Testing: Dissolution, Disintegration, Hardness, and Friability." Journal of Pharmaceutical Sciences and Research, 5(2), 116-122.
  28. Tosun, A. (2012). "Quality Control Testing of Pharmaceutical Tablets." Journal of Applied Pharmaceutical Science, 2(7), 34-39.
  29. Garg, S., & Gupta, G. D. (2014). "Dissolution Testing of Pharmaceutical Dosage Forms." Indian Journal of Pharmaceutical Sciences, 76(1), 1-8.
  30. Bajaj, A., & Khurana, V. (2017). "Testing of Pharmaceutical Tablets: Techniques and Instruments." Asian Journal of Pharmaceutical Technology and Innovation, 5(9), 1-6.
  31. Lachman, L., Lieberman, H. A., & Kanig, J. L. (1991). "The Theory and Practice of Industrial Pharmacy" (3rd Edition). Bombay: Varghese Publishing House.
  32. Shargel, L., Wu-Pong, S., Yu, A. B. C. (2012). "Applied Biopharmaceutics & Pharmacokinetics" (6th Edition). McGraw-Hill Education.
  33. ICH Q8(R2) – Pharmaceutical Development Guidelines Focuses on granulation, drying, and compression for solid dosage forms.
  34. USP General Chapter <1174> Powder Flow o Guidelines for granule flowability before tablet compression.
  35. Pharmaceutical Powder Technology – Martin’s Physical Pharmacy & Pharmaceutical Sciences (7th Edition).
  36. British Pharmacopoeia (BP) – Sieving Techniques & Particle Size Distribution o British Pharmacopoeia .
  37. USP General Chapter <786> "Particle Size Distribution Estimation by Analytical Sieving.
  38. United States Pharmacopeia (USP) – General Chapter <1062> "Tablet Compression" Provides guidance on tablet hardness, thickness, and weight variation.
  39. European Pharmacopoeia (EP) – Tablet Compression Standards European Pharmacopoeia.

Photo
Kaushal Borkar
Corresponding author

P. Wadhwani College of Pharmacy Yavatmal.

Photo
Dr. M. D. kitukale
Co-author

P. Wadhwani College of Pharmacy Yavatmal.

Photo
Gayatri Argulwar
Co-author

P. Wadhwani College of Pharmacy Yavatmal.

Photo
Sanket Deshmukh
Co-author

P. Wadhwani College of Pharmacy Yavatmal.

Photo
Shilpa Jaiswal
Co-author

P. Wadhwani College of Pharmacy Yavatmal.

Kaushal Borkar*, Gayatri Argulwar, Sanket Deshmukh, Shilpa Jaiswal, Dr. M. D. Kitukale, Formulation and Evaluation of a Polyherbal Anticancer Tablet Containing Moringa Oleifera and Tulsi, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 7, 1067-1084. https://doi.org/10.5281/zenodo.15835925

More related articles
Comparative Efficacy of Nutraceuticals and Convent...
Arnab Roy, Sajid Ansari, Faiz Alam , Chandan Kumar, Ayush Kumar, ...
Study The Epidemiology, Pathology And Prior Epidem...
Arshit Thakur, Abhishek katwal, Palvi Sharma, ...
Formulation And Evaluation Of Colon Target Matrix Tablet Of Mesalamine Using Syn...
Ritesh Rana, Akshit Sharma, Parshuram Rai, Priyanka Devi, ...
Innovative Gastroprotective Systems Utilizing Natural Polymers for Glipizide and...
Monika Bairagi, Khemendra Kumar Chaturvedi, Dr. Yogesh Pounikar, ...
Doxycycline induced Urticaria: A Case Report...
Mitta Putta Pooja, Kiranmai Venkatagiri, Sandeep Reddy Ambati, Bhavya Sai Sakhamuri, Sai Keshava Red...
Related Articles
Anti-Proliferative Effect of Methanolic Extract from Philodendron Burle-Marxii ...
Prabitha E. G., T. P. Rajmohanan, Ajna P. A., Anjali U., Binil Raj S. S., ...
Herbal Remedy for Stomach Pain: Formulation and Efficacy...
Kadam Bhagyashri , Shete Pooja , Aher Aniruddha , Sabale J. V., ...
More related articles
Comparative Efficacy of Nutraceuticals and Conventional Medicines in Hypertensio...
Arnab Roy, Sajid Ansari, Faiz Alam , Chandan Kumar, Ayush Kumar, Alijan Mansur, Shahid Afridi, Md. A...
Comparative Efficacy of Nutraceuticals and Conventional Medicines in Hypertensio...
Arnab Roy, Sajid Ansari, Faiz Alam , Chandan Kumar, Ayush Kumar, Alijan Mansur, Shahid Afridi, Md. A...